The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
‘ The Company’s diagnostics product lines cover virtually all blood tests routinely performed in hospital laboratories. For medical and pharmaceutical research, they provide a wide range of systems used in genomic, cellular and protein testing. The Company has approximately 125 000 systems operating in laboratories around the world, with 68% of annual revenues coming from after-market customer purchases of operating supplies, chemistry kits and service. Beckman Coulter markets their products in approximately 130 countries.’
https://www.bionity.com/en/companies/13213/beckman-coulter-u-k-limited.html
We had an indication in one of the presentations that DB was not concerned about their ability to scale up.
Magsy - no confirmation
However i have seen the odd word when the 10,000 is mentioned that its not set in stone.
Even 1m a week with $1 profit is wishful thinking, but its not out of the realms of impossibility, especially if supply is split between a few customers.
1m a week split over 10 labs in different geographies is doable. With each lab having 100k tests each (realistic number). There is a lot of play in these numbers and they can be arranged to suit anyones agenda so i hope this isnt coming across as a ramp. With $1 profit on each bead its lucrative.
my understanding is that at the moment we have one work station/machine/line to produce from which can churn out 10k an hour. we can increase output by either increasing number of hours its in use or by adding another work station/machine/line or both. My guess is that we would have little issue getting as many workstation/lines as we need due to the interconnectedness (is that even a word) of the companies involved.
so we start by increasing hours the first line is working then when that maxed out add workstations/lines.
i would imagine materials would be the limiting factor not the amount we can make, but then our new partners i am sure will help with that.
Prediction. we don't actually have to worry about getting to far down this route after we have proved it works. My guess (again) is that we are brought out at this stage. lets be entirely honest a company with great ideas and 45 employees is not going to be able to cope with this sort of demand with out some major changes.
makes sense to me
Safy, have we had any confirmation that we are able to scale up to 24/7 shift patterns? If we did that, we get 1.7m a week right?
There was an open question a while back as to whether the manufacturing process could be scaled horizontally i.e. be able to manufacture 20k or 30k per hour.
safy, thanks for that. Valid points.
@Gloria
Given that we can supply circa 2m tests a weeks if we work flat out 24/7, i dont really care if they sell them to Beckman for peanuts. Sales are sales.
Its wishful thinking to sell everything but if we get $1 dollar profit a test and sell everything ill be over the moon. Even $0.5 and sell everything ill still be over the moon.
Also if you had sense you would know that in any sales there is such a thing as promoter score and reference, these are massively useful for future sales as you can call on your other partners to vouch for you. Well prior to yesterday there wasnt exactly a big list of people we can call on.
Now lets put this into context, Beckman saying GDR are good, and that we use GDR tests in our lab(s), instead of the (fill this space yourself based on how crap you think GDR are) saying GDR are good.
If anyone follows them British bulls have GDR as a buy... im aware they change position like the wind before any silly comments
87p paid again
wont really matter when Beckman buys Genedrive :)
Bullish reversal on the short term chart
Don't be surprised with a blue finish here
Anyone know GDRs profit margin wrt to the deal with Beckman? I don't think that's been disclosed and I doubt it ever will be tbh.
Buyers did step in when bid advertised 83p
Let's see if its a trap
Well I’ve dabbled a few times again this morning.
It may well go down a bit more, but this is all short term movements which will become irrelevant when next news drops (multiple candidates as we all know).
PP
NCYT having a solid start. Only one that has commercialised so makes sense..
Another rough day for COVID Stocks:
0QYQ -0.8
AVCT -2.3
DDDD -4.8
IDH -1.9
ODX -3.54
SKIN -0.47
SNG -1.1
MTPH +1.6
NCYT +1.7
GDR -2.2
I don't see 78p happening
Bottom 82p
Target 108-110p
Bottom 78....Target £1
Could touch 82-83p quickly but hopefully buyers step in
MM's looking for liquidity
Down on thin trading, as soon as volume dries up MM take the price down to force sellers out, of which there are few. Hopefully this will reverse throughout the day.
Down we go once again. What’s Zaks target?
make that 90.10....where's Punit
90-95 spread / 92.5
PP
92.20
What’s the live sp pls?